Pretransplant and early posttransplant predictors of chronic allograft nephropathy in cadaveric kidney allograft - A single-center analysis of 1112 cases

Transplant International

Volumn 17, Issue 2, 2004, Pages 78-88

  Lietz, Katarzyna ^a   Lewandowski, Zbigniew ^a   Lao, Mieczyslaw ^a   Paczek, Leszek ^a   Gaciong, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Chronic allograft nephropathy; Transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; METHYLPREDNISOLONE; OKT 3; PREDNISONE; THYMOCYTE ANTIBODY;

ADULT; CADAVER KIDNEY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DATA ANALYSIS; DISEASE MARKER; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ADULT; CADAVER; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 1542314380     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00147-003-0664-5     Document Type: Review

References (57)

1. Cecka M. Clinical outcome of renal transplantation. Factors influencing patient and graft survival. Surg Clin North Am 1998; 78:133.
2. Paul LC. Chronic allograft nephropathy: an update. Kidney Int 1999; 56:783.
3. Fellström BC, Larsson E. Pathogenesis and treatment perspectives of chronic graft rejection (CGR). Immunol Rev 1993; 134:83.
4. Häyry P. Chronic rejection: an update on the mechanism. Transplant Proc 1998; 30:3993.
5. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44:411.
6. Modena FM, Hostetter TH, Salahudeen AK, Najarian JS, Matas A, Rosenberg ME. Progression of kidney disease in chronic renal transplant rejection. Transplantation 1991; 52:239.
7. Koyama H, Cecka JM. Rejection episodes. Clin Transpl 1992: 391.
8. 1/2). Transplantation 1994; 57:857.
9. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55:993.
10. Tejani A, Cortes L, Stablein D. Clinical correlates of chronic rejection in pediatric renal transplantation. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 1996; 61:1054.
11. Isoniemi H, Kyllönen L, Eklund B, et al. Acute rejection under triple immunosuppressive therapy does not increase the risk of late first cadaveric renal allograft loss. Transplant Proc 1995; 27:875.
12. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Bertram LK. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kindey Int 1996; 49:518.
13. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55:752.
14. Held PJ, Kahan BD, Hunsicker LG, et al. The impact of HLA mismatches on the survival of first dcadaveric kidney transplants. N Engl J Med 1994; 331:765.
15. Kahan BD. Cyclosporine: a base for therapy present and future. Transplant Proc 1993; 25:508.
16. Salomon DR. An alternative view minimizing the significance of cyclosporine nephrotoxicity and in favor of enhanced immunosuppression for long-term kidney transplant recipients. Transplant Proc 1991; 23:2115.
17. Nickerson P, Jeffery J, Gough J, et al. Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol 1998; 9:482.
18. Isoniemi HM, Ahonen J, Tikkanen MJ, et al. Long-term consequences of different immunosuppressive regimens for renal allografts. Transplantation 1993; 55:494.
19. Thiel G, Bock A, Spondlin M, et al. Long-term benefits and risks of cyclosporin A (Sandimmun): an analysis at 10 years. Transplant Proc 1994; 26:2493.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457.
21. Cox DR. Regression models and life tables (with discussion) J R Stat Soc 1972; B34:187.
22. Beckingham IJ, O'Rourke JS, Stubington SR, Hinwood M, Bishop MC, Rigg KM. Impact of cyclosporin on the incidence and prevalence of chronic rejection in renal transplants. Ann R Coll Surg Engl 1997; 79:138.
23. Brenner BM, Cohen RA, Milford EL. In renal transplantation, one size may not fit all. J Am Soc Nephrol 1992; 3: 162.
24. Kim HC, Suk J, Joo I, Park SB, Cho WH, Park CH. Risk factors for chronic rejection in renal allograft recipients. Transplant Proc 1999; 28:1456.
25. Längle F, Sautner T, Grünberger T, et al. Impact of donor age on graft function in living-related kidney transplantation. Transplant Proc 1992; 24: 2725.
26. Hostetter TH. Chronic transplant rejection. Kidney Int 1994; 46:266.
27. Lee LS, Auersvald LA, Claus EB, et al. Body size mismatch between donor and recipient and the development of chronic rejection in renal transplantation. Transplant Proc 1997; 29:111.
28. Cecka JM. The UNOS Scientific Renal Transplant Registry. Clin Transpl 1996: 1.
29. Takada M, Nadeau KC, Hancock WW, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 1998; 65:1533.
30. Power BM, van Heerden PV. The physiological changes associated with brain death: current concepts and implications for the treatment of the brain-dead donor. Anaesth Intensive Care 1995; 23:26.
31. Herijgers P, Leunens V, Tjandra-Maga TB, Mubagwa K, Flameng W. Changes in organ perfusion after brain death in the rat and its relation to circulating catecholamines. Transplantation 1996; 62:330.
32. Mertes PM. Physiology of brain death. In: Tilney NL, Strom TB, Paul LC, eds. Transplantation biology: cellular and molecular aspects. Philadelphia, Lippincott, 1996: 275.
33. Gjertson DW. A multi-factor analysis of kidney graft outcomes at one and five years posttransplantation: 1996 UNOS update. Clin Transpl 1996: 343.
34. Lagiewska B, Pacholczyk M, Szostek M, Walaszewski J, Rowinski W. Hemodynamic and metabolic disturbances observed in brain-dead organ donors. Transplant Proc 1996; 28:165.
35. Tilney NL, Guttman RD. Effects of initial ischemia/reperfusion injury on the transplanted kidney. Transplantation 1997; 64:945.
36. Koo DD, Welsh KI, McLaren AJ, Roake JA, Morris PJ, Fuggle SV. Cadaver versus living donor kidneys: impact of donor factors on antigen induction before transplantation. Kidney Int 1999; 56:1551.
37. Takada M, Nadeau KC, Shaw GD, Marquette KA, Tilney NL. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. J Clin Invest 1997; 99:2682.
38. Kusaka M, Pratschke J., Wilhelm MJ, et al. Activation of proinflammatory mediators in rat renal isografts by donor brain death. Transplantation 2000; 69:405.
39. Pratschke J, Wilhelm MJ, Kusaka M, et al. Accelerated rejection of rat renal allografts from brain-dead donors. Ann Surg 2000; 232:263.
40. Wilhelm MJ, Pratschke J, Beato F, et al. Activation of the heart by donor brain death accelerates acute rejection after transplantation. Circulation 2000; 102:2426.
41. Pratschke J, Markus JW, Laskowski I, et al. Influence of donor brain death on chronic rejection of renal transplants in rats. J Am Soc Nephrol 2001; 12:2474.
42. Meier-Kriesche HU, Ojo AO, Cibrik DM, et al. Relationship of recipient age and development of chronic allograft failure. Transplantation 2000; 70:306.
43. Cameron JS. Renal transplantation in the elderly. Int Urol Nephrol 2000; 32:193.
44. John R, Lietz K, Schuster M, et al. Older recipient age is associated with reduced alloreactivity and graft rejection after cardiac transplantation. J Heart Lung Transplant 2001; 20:212.
45. Vella JP, O'Neill D, Atkins N, Donohoe JF, Walshe JJ. Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Nephrol Dial Transplant 1998; 13:2027.
46. Friedlaender MM, Azem O, Rubinger D, Brautbar C. Effect of human recombinant erythropoeitin therapy on panel-reactive antibodies in chronic dialysis patients. Isr J Med Sci 1996; 32: 730.
47. Pfaffl W, Gross JH, Neumeier D, Nattermann U, Samtleben W, Gurland HJ. Lymphocyte subsets and delayed cutaneous hypersensitivity in hemodialysis patients receiving recombinant human erythropoetin. Contrib Nephrol 1988; 66:195.
48. Imiela J, Korczak-Kowalska G, Malecki R, Nowaczyk M, Stepien-Sopniewska B, Gorski A. Immunomodulatory action of human recombinant erythropoietin in man. Immunol Lett 1993; 35:271.
49. Kimball PM, Kerman RH. Erythropoietin: a potential immunomodulator? Transplant Proc 1991; 23:336.
50. Kimata H, Yoshida A, Ishioka C, Masuda S, Sasaki R, Mikawa H. Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum free medium. Clin Exp Immunol 1991; 85:151.
51. Steffensen G, Aunsholt NA, Povlsen JV. Evidence that treatment of ESRD patients with recombinant human erythropoietin induces immunosuppression without affecting the distribution of peripheral blood mononuclear cell subpopulations. Clin Nephrol 1996; 45:98.
52. Grimm PC, Sinai-Trieman L, Sekiya NM, et al. Effects of recombinant human erythropoietin on HLA sensitization and cell-mediated immunity. Kidney Int 1990; 38:12.
53. Grimm PC, Sekiya NM, Robertson LS, Robinson BJ, Ettenger RB. Recombinant human erythropoietin decreases anti-HLA sensitivity and may improve renal allograft outcome: involvement of anti-idiotypic antibody. Transplant Proc 1991; 23:407.
54. Lechevallier E, Dussol B, Luccioni A, et al. Posttransplantation acute tubular necrosis: risk factors and implications for graft survival. Am J Kidney Dis 1998; 32:984.
55. Matas AJ, Gillingham KJ, Humar A, Dunn DL, Sutherland DER, Najarian JS. Immunologic and nonimmunologic risk factors: different risk factors for cadaver and living donor transplantation. Transplantation 2000; 69:54.
56. Massy ZA, Kasiske BL. Post-transplant hyperlipidemia: mechanisms and management. J Am Soc Nephrol 1996; 7:971.
57. Guijarro C, Massy ZA, Kasiske BL. Clinical correlation between renal allograft failure and hyperlipidemia. Kidney Int 1995; 48:S56.